Insulet Corp. (PODD) Stock Analysis & Investment Frameworks
Insulet Corp. (PODD) stock analysis on Invetso. Review Insulet Corp.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Insulet Corp. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
Insulet Corp. Key Financial Metrics
- Market Cap: $10.16B
- Revenue: $2.71B
- P/E Ratio: 41.15
- ROE: 29.48%
- ROIC: 17.53%
- Dividend Yield: N/A
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.